Champions Oncology Inc (CSBR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $65.49M
Last updated: Nov 17, 2026 at 10:50 AM ET
Champions Oncology Inc (CSBR) Financials: Revenue, Profit and Cash Flow
Champions Oncology reported revenue of $59.42M for the fiscal year ended Apr 30, 2026, up 4.4% from the year before. That year, net income was -$1.18M with a net margin of -2.0%, operating cash flow was -$4.47M and free cash flow was -$5.04M. The quarter ended Jul 31, 2026 had revenue of $15.23M and net income of -$426.00K.
Revenue and Margins
The operating margin was -1.9% in the fiscal year ended Apr 2026. Over the 9 years to Apr 2026, revenue grew from $15.41M, a compound annual rate of 16.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Apr 2026 | $59.42M | +4.4% | 48.0% | -1.9% | -2.0% |
| Apr 2025 | $56.94M | +13.5% | 50.1% | 8.0% | 8.3% |
| Apr 2024 | $50.16M | -6.9% | 41.4% | -14.7% | -14.5% |
| Apr 2023 | $53.87M | +9.7% | 45.2% | -9.8% | -9.9% |
| Apr 2022 | $49.11M | +19.7% | 51.9% | 1.2% | 1.1% |
| Apr 2021 | $41.04M | +27.8% | 47.7% | 0.9% | 0.9% |
| Apr 2020 | $32.12M | +18.7% | 47.1% | -6.0% | -6.5% |
| Apr 2019 | $27.07M | +33.7% | 100.0% | 1.0% | 0.5% |
| Apr 2018 | $20.24M | +31.3% | 100.0% | -6.7% | -7.3% |
| Apr 2017 | $15.41M | N/A | 100.0% | -44.2% | -44.7% |
Income Statement
In the fiscal year ended Apr 2026, the company posted a net loss after a profit the year before. In the quarter ended Jul 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59.42M | $56.94M | $50.16M | $53.87M | $49.11M | $41.04M | $32.12M | $27.07M | $20.24M | $15.41M |
| Cost of revenue | $30.90M | $28.39M | $29.40M | $29.53M | $23.63M | $21.45M | $17.00M | $0 | $0 | $0 |
| Gross profit | $28.52M | $28.55M | $20.75M | $24.34M | $25.48M | $19.59M | $15.12M | $27.07M | $20.24M | $15.41M |
| Research and development | $9.08M | $6.83M | $9.54M | $11.54M | $9.37M | $7.20M | $5.85M | $4.80M | $4.40M | $4.29M |
| Operating income | -$1.14M | $4.55M | -$7.36M | -$5.26M | $607.00K | $366.00K | -$1.92M | $270.00K | -$1.35M | -$6.81M |
| Net income | -$1.18M | $4.70M | -$7.28M | -$5.33M | $548.00K | $362.00K | -$2.09M | $128.00K | -$1.48M | -$6.88M |
| EBITDA | $448.00K | $6.27M | -$5.44M | -$3.02M | $2.21M | $1.62M | -$1.14M | $837.00K | -$1.08M | -$6.70M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.23M | $13.84M | $16.56M | $15.04M | $13.99M | $12.36M | $17.04M | $13.49M | $14.06M | $14.00M | $12.02M | $11.57M |
| Gross profit | $7.70M | $7.03M | $7.72M | $7.77M | $6.00M | $5.08M | $10.42M | $6.06M | $6.99M | $6.75M | $4.17M | $4.96M |
| Operating income | -$409.00K | -$522.00K | -$276.00K | $185.00K | -$527.00K | -$2.01M | $4.50M | $732.00K | $1.33M | -$272.00K | -$2.58M | -$1.96M |
| Net income | -$426.00K | -$667.00K | -$279.00K | $237.00K | -$466.00K | -$1.83M | $4.50M | $728.00K | $1.31M | -$109.00K | -$2.53M | -$2.07M |
Balance Sheet
As of Apr 2026, cash and equivalents of $4.87M were 18.0% of total assets of $26.99M, against total liabilities of $22.92M.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $26.99M | $32.34M | $26.13M | $34.31M | $35.38M | $27.59M | $20.75M | $11.27M | $8.08M | $8.01M |
| Current assets | $19.22M | $22.36M | $13.64M | $19.46M | $19.66M | $12.63M | $13.50M | $7.92M | $5.06M | $5.87M |
| Cash and equivalents | $4.87M | $9.79M | $2.62M | $10.12M | $9.01M | $4.69M | $8.34M | $3.24M | $856.00K | $3.29M |
| Total liabilities | $22.92M | $28.57M | $28.04M | $29.68M | $26.28M | $20.16M | $15.65M | $9.03M | $8.07M | $7.61M |
| Short-term debt | N/A | $1.47M | $1.34M | $1.21M | $1.05M | $818.00K | $628.00K | $16.00K | $26.00K | $25.00K |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $16.00K | $38.00K |
| Shareholder equity | $3.94M | $3.77M | -$1.90M | $4.64M | $9.10M | $7.43M | $5.10M | $2.24M | $3.00K | $400.00K |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $33.29M | $26.99M | $28.45M | $30.16M | $30.55M | $32.34M | $30.63M | $25.24M | $24.93M | $26.13M | $26.79M | $28.29M |
| Total liabilities | $28.83M | $22.92M | $24.07M | $25.93M | $27.01M | $28.57M | $25.16M | $24.56M | $25.27M | $28.04M | $28.84M | $28.20M |
| Cash and equivalents | $4.36M | $4.87M | $7.13M | $8.52M | $10.32M | $9.79M | $3.20M | $2.75M | $2.89M | $2.62M | $4.47M | $5.51M |
| Shareholder equity | $3.89M | $3.94M | $4.28M | $4.17M | $3.51M | $3.77M | $5.47M | $681.00K | -$332.00K | -$1.90M | -$2.06M | $93.00K |
Cash Flow
Operating cash flow was negative in the fiscal year ended Apr 2026.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.47M | $7.39M | -$6.14M | $3.97M | $6.50M | -$1.68M | $2.90M | $1.86M | -$1.23M | -$2.84M |
| Capital expenditures | $564.00K | $389.00K | $836.00K | $2.87M | $2.38M | $3.28M | $2.22M | $834.00K | $1.23M | $766.00K |
| Free cash flow | -$5.04M | $7.00M | -$6.97M | $1.10M | $4.11M | -$4.96M | $685.00K | $1.03M | -$2.46M | -$3.61M |
| Share repurchases | N/A | $0 | $634.00K | $74.00K | $0 | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$540.00K | -$389.00K | -$836.00K | -$2.87M | -$2.38M | -$3.17M | -$2.22M | -$834.00K | -$1.23M | -$766.00K |
| Financing cash flow | $99.00K | $170.00K | -$527.00K | $11.00K | $207.00K | $1.20M | $4.42M | $1.20M | $13.00K | $4.32M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$492.00K | -$2.00M | -$1.34M | -$1.74M | $600.00K | $6.87M | $490.00K | -$283.00K | $311.00K | -$1.82M | -$919.00K | $589.00K |
| Capital expenditures | $55.00K | $239.00K | $37.00K | $242.00K | $46.00K | $253.00K | $42.00K | $94.00K | $0 | $3.00K | $92.00K | $79.00K |
| Free cash flow | -$547.00K | -$2.24M | -$1.38M | -$1.98M | $554.00K | $6.62M | $448.00K | -$377.00K | $311.00K | -$1.82M | -$1.01M | $510.00K |
Frequently Asked Questions About CSBR
What is Champions Oncology's annual revenue?
Champions Oncology reported revenue of $59.42M for the fiscal year ended Apr 30, 2026.
How fast is Champions Oncology's revenue growing?
Revenue was up 4.4% for the fiscal year ended Apr 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 3.3%.
Is Champions Oncology profitable?
No. Champions Oncology reported net income of -$1.18M for the fiscal year ended Apr 30, 2026, with a net margin of -2.0%.
How much free cash flow does CSBR generate?
For the fiscal year ended Apr 30, 2026, operating cash flow of -$4.47M minus capital expenditures of $564.00K produced free cash flow of -$5.04M.
How much debt does Champions Oncology have?
The balance sheet dated Apr 30, 2026 reported cash and equivalents of $4.87M.
CSBR pages: Overview, Earnings, Financials, Valuation, Competitors